Article Text

Download PDFPDF
042 Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thromboelastography?
  1. V Amoah1,
  2. A M Worrall1,
  3. A R Hobson2,
  4. A Smallwood1,
  5. R Rajendra3,
  6. J Vickers3,
  7. A M Nevill3,
  8. S Dunmore3,
  9. N Curzen2,
  10. J M Cotton1
  1. 1New Cross Hospital, Wolverhampton, UK
  2. 2Wessex Cardiac Centre, Southampton, UK
  3. 3University of Wolverhampton, Wolverhampton, UK


Introduction Many centres already use the thrombelastograph (TEG) Haemostasis Analyser to monitor whole blood clotting parameters following cardiothoracic and other surgical procedures. Our group has modified this technique (short TEG, sTEG), to allow the rapid identification of aspirin and clopidogrel hypo-responsiveness. We sought to validate the sTEG area under curve (AUC)15 parameter, in patients admitted with acute coronary syndromes (ACS) by comparing sTEG with the VerifyNow (VN) analyser, and vasodilator-stimulated phosphoprotein (VASP) assay.

Methods Forty-nine patients admitted with ACS and planned for angiography were studied. All had either ECG changes of ischaemia and/or a raised Troponin I. Aspirin and clopidgrel loading were as per contemporary UK practice. Whole blood samples were collected after sheath insertion. The sTEG AUC15 in response to ADP was calculated using a specially developed software programme. Samples were also analysed using the VN (Accumetrics, California, USA) system as per the manufacturers` instructions and VASP assay was performed within 12 h of sampling using a commercial system. The clinical endpoint was adverse clinical events (ACE) at 12 months (death, myocardial infarction (MI), repeat revascularisation (RR), stroke or unplanned cardiovascular hospitalisation (UCH).

Results Of the 49 patients investigated (mean age 63 (39–87), 16 female) successful readings were obtained for sTEG, VN P2Y12 and VASP in 47, 49 and 39 subjects respectively. The mean sTEG AUC15 was 742.1±295.6 mm/min, mean VN platelet response units (PRU) was 235.3±105, and mean VASP platelet reactivity index (PRI) 49.3±20.6%. These three variables were normally distributed. sTEG AUC15 correlated with VN PRU r2=0.54, p<0.0001 (Abstract 42 Figure 1a), with a weaker, but significant correlation seen with VASP PRI r2=0.26, p=0.001 (Abstract 42 Figure 1b). Previous studies have estimated a clinically relevant clopidogrel response cut off point VN PRU of 240. In our study, individuals with a PRU ≥240 had significantly greater mean AUC15 compared to those with <240 (911±195, n=29 vs 493±238, n=19, p=<0.0001) (Abstract 42 Figure 2a). sTEG AUC15, using a cut off of 800 mm/min (Abstract 42 Figure 2b) and VN PRU using a cut off of 240 predicted ACE at 1 year (p<0.02). During the follow up period there were 5 (10%) ACE (1 MI, 1 RR, and 3 UCH).

Abstract 42 Figure 1

VN, VerifyNow; PRU, platelet response units; VASP, vasodilator-stimulated phosphoprotein; PRI, platelet reactivity index; AUC, area under curve; ADP, adenosine diphosphate.

Abstract 42 Figure 2

sTEG, short TEG; AUC, area under curve; PRU, platelet response units.

Conclusions This study demonstrates that sTEG, a simple, time responsive technique correlates with VN and VASP methods, and in the studied group identified a cohort of patients with ACE at 1 year. However, further large scale trials of this technique are required to verify this finding.

  • thromboelastography
  • clopidogrel
  • VerifyNow

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.